Is there an obligatory need for an oncological treatment modality if helicobacter pylori eradication is not followed by complete regression of gastric low-grade lymphoma of malt-type?

Kolve–Goebeler, Maria–Elisabeth; Fischbach, Wolfgang

doi:10.1016/s0016-5085(00)85174-4

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Möglicherweise ist dies aber gar nicht erforderlich und eine Watch-and-wait-Strategie angebracht. Sieben Patienten mit «minimal residual disease» ließen über Jahre hinweg keine Progression erkennen [5]. Zwischenzeitlich überblicken wir eine Serie von 23 Patienten, die ohne Ausnahme einen günstigen Verlauf ohne klinisches Rezidiv, Dissemination oder hochmaligne Transformation zeigen [6].…”

Section: Gastrointestinal Lymphomas: Perspectives and Future Therapeuunclassified

Gastrointestinale Lymphome: Ausblick und zukünftige Therapiestrategien

Fischbach¹,

Dragosics²

2002

Visc Med

View full text Add to dashboard Cite

Gastrointestinal Lymphomas: Perspectives and Future Therapeutic Options Considering the histological grade of malignancy and dissemination (stage) of disease as decisive prognostic factors and therapeutic determinants, a subtle endoscopic bioptical diagnosis (gastric mapping) is of particular importance. Push enteroscopy and capsule endoscopy can be expected to diagnose an intestinal lymphoma without surgical intervention more often than previously. They also offer an opportunity to establish the frequency of a multiorganic manifestation of gastrointestinal lymphoma. Conventional endoscopic ultrasound represents an obligatory investigation when staging the patients. The use of high-resolution mini-echoendoscopes and endosonographically guided puncture will probably improve the diagnostic accuracy. Future therapeutic strategies comprise Helicobacter pylori eradication therapy in higher stages (>I) of low-grade lymphoma and in patients with localized high-grade lymphoma under strict study conditions as well as a watch-and-wait strategy in those with minimal residuals of lymphoma revealed by histology after successful treatment of Helicobacter pylori . The clinical value of anti-CD20 antibody therapy is currently unclear. With respect to the classical oncological treatment modalities, future activities will focus on the reduction of treatment-related toxicities and of long-term complications while offering a high therapeutic efficacy.

show abstract

Section: Gastrointestinal Lymphomas: Perspectives and Future Therapeuunclassified

Gastrointestinale Lymphome: Ausblick und zukünftige Therapiestrategien

Fischbach¹,

Dragosics²

2002

Visc Med

View full text Add to dashboard Cite

show abstract

Conservative treatment of primary gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue: predictive factors of response and outcome

Lévy¹,

Copie‐Bergman²,

Traulle³

et al. 2002

Am J Gastroenterology

View full text Add to dashboard Cite

The major negative predictive factor of the tumoral response to anti-H. pylori treatment in patients with primary gastric low-grade B-cell lymphoma of mucosaassociated lymphoid tissue was the presence of perigastric lymph nodes on endoscopic ultrasonography. In responding patients, remission remained stable, suggesting that adjuvant chemotherapy was not useful. In patients who failed to respond to H. pylori eradication, monochemotherapy with chlorambucil proved to be efficient, but new therapeutic modalities should be evaluated to improve the control of the tumoral process.

show abstract

Is there an obligatory need for an oncological treatment modality if helicobacter pylori eradication is not followed by complete regression of gastric low-grade lymphoma of malt-type?

Cited by 2 publications

References 0 publications

Gastrointestinale Lymphome: Ausblick und zukünftige Therapiestrategien

Gastrointestinale Lymphome: Ausblick und zukünftige Therapiestrategien

Conservative treatment of primary gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue: predictive factors of response and outcome

Contact Info

Product

Resources

About